OX40 agonism enhances PD-L1 checkpoint blockade by shifting the cytotoxic T cell differentiation spectrum

Immune checkpoint therapy (ICT) has the power to eradicate cancer, but the mechanisms that determine effective therapy-induced immune responses are not fully understood. Here, using high-dimensional single-cell profiling, we interrogate whether the landscape of T cell states in the peripheral blood...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Sluis, Tetje C., Beyrend, Guillaume, van der Gracht, Esmé T.I., Abdelaal, Tamim, Jochems, Simon P., Belderbos, Robert A., Wesselink, Thomas H., van Duikeren, Suzanne, van Haften, Floortje J., Redeker, Anke, Ouboter, Laura F., Beyranvand Nejad, Elham, Camps, Marcel, Franken, Kees L.M.C., Linssen, Margot M., Hohenstein, Peter, de Miranda, Noel F.C.C., Mei, Hailiang, Bins, Adriaan D., Haanen, John B.A.G., Aerts, Joachim G., Ossendorp, Ferry, Arens, Ramon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040386/
https://www.ncbi.nlm.nih.gov/pubmed/36796366
http://dx.doi.org/10.1016/j.xcrm.2023.100939

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10040386/
https://www.ncbi.nlm.nih.gov/pubmed/36796366
http://dx.doi.org/10.1016/j.xcrm.2023.100939

Ejemplares similares